Innoforce Names Dewan Zeng CEO

Zhejiang Innoforce Pharmaceuticals Co., Ltd., a CDMO that provides services for advanced therapy medicinal product (ATMP), appointed Dewan Zeng Chief Executive Officer, effective immediately. Yuling Li will continue to focus on technology innovation and CDMO operations as President.

Zeng is an internationally recognized pharmaceutical product and business development leader. She has successfully leveraged her technical insights and leadership skills to foster organizational growth in several previous companies. Prior to joining Innoforce, Zeng was vice president, global head of search and evaluation, and business development at BeiGene, where she played a critical role in several transformative deals between BeiGene and other multi-national pharmaceutical companies. She was also a global program lead for over 20 clinical-stage assets at CV Therapeutics, Gilead, and Pfizer, where she was responsible for clinical and regulatory strategy and oversight of key clinical studies of those programs. She supported IND submission for twenty investigational products and NDA approval of three innovative products in the U.S., Europe, and China.

“Innoforce was established with the vision to enable and accelerate the development and commercialization of innovative therapeutics,” said Guo-Liang Yu, Chairman of Innoforce. “With the enhancement of our leadership, we can now realize our vision at an accelerated pace. Dr. Zeng brings broad global experiences in high-performing pharmaceutical companies. I am confident in her ability to lead Innoforce through the next chapter.”

Zeng said, “I am thrilled to be joining Innoforce and am inspired by its strategy to become a leader in process development and manufacturing of ATMPs; I look forward to working with our leadership team and our partners to bring more effective medicines to patients around the world.”